Tallac Therapeutics
Burlingame, US · 4 known investors
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment. Its pipeline includes multiple programs in discovery and clinical development.
BiotechHealthtech
Investors · 4
Competitors · 4
by search overlapDialectic Therapeutics15 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Relay13 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Solu12 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Trisaluslifesci10 shared keywordsTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Companies competing with Tallac Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Tallac Therapeutics do?
- Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment. Its pipeline includes multiple programs in discovery and clinical development.
- Who are Tallac Therapeutics's investors?
- Tallac Therapeutics's investors include Lightstone Ventures, MRL Ventures Fund, venBio Partners, venBio Global Strategic.
- Where is Tallac Therapeutics headquartered?
- Tallac Therapeutics is headquartered in Burlingame, US.